February 2024
1. CHOI H, Cho SW, Kim HH, Yi KH, et al
   Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma.
   Cancer. 2024 Feb 20. doi: 10.1002/cncr.35256.
   

   >> Share

   
   May 2023
2. 
   Erratum to "Concordance in postsurgical radioactive iodine therapy recommendations between Watson for Oncology and clinical practice in patients with differentiated thyroid carcinoma".
   Cancer. 2023 May 2. doi: 10.1002/cncr.34829.
   

   >> Share

   
   April 2023
3. YAN L, Li Y, Li XY, Xiao J, et al
   Clinical outcomes of ultrasound-guided radiofrequency ablation for solitary T1N0M0 papillary thyroid carcinoma: A retrospective study with more than 5 years of follow-up.
   Cancer. 2023 Apr 15. doi: 10.1002/cncr.34802.
   

   >> Share

   
   February 2023
4. OH DY, Algazi A, Capdevila J, Longo F, et al
   Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.
   Cancer. 2023 Feb 7. doi: 10.1002/cncr.34657.
   

   >> Share

   
   January 2023
5. 
   Erratum to "Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial".
   Cancer. 2023 Jan 13. doi: 10.1002/cncr.34638.
   

   >> Share

   
   October 2022
6. BROSE MS, Robinson BG, Sherman SI, Jarzab B, et al
   Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
   Cancer. 2022 Oct 19. doi: 10.1002/cncr.34493.
   

   >> Share

   
   April 2022
7. KIYOTA N, Tahara M, Robinson B, Schlumberger M, et al
   Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
   Cancer. 2022 Apr 5. doi: 10.1002/cncr.34181.
   

   >> Share

   
   October 2021
8. CHEMAITILLY W, Li Z, Brinkman TM, Delaney A, et al
   Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences.
   Cancer. 2021 Oct 13. doi: 10.1002/cncr.33969.
   

   >> Share

   
   July 2021
9. ROMESSER PB, Sherman EJ, Whiting K, Ho ML, et al
   Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial.
   Cancer. 2021 Jul 22. doi: 10.1002/cncr.33804.
   

   >> Share

   
   
10. XIAO Q, Kitahara CM
    Reply to associations between light at night and risk of thyroid cancer.
    Cancer. 2021 Jul 10. doi: 10.1002/cncr.33685.
    

    >> Share

    
    
11. XIAO P, Li L, Ding S, Xie J, et al
    Associations between light at night and risk of thyroid cancer.
    Cancer. 2021 Jul 10. doi: 10.1002/cncr.33686.
    

    >> Share

    
    February 2021
12. ZHANG D, Jones RR, James P, Kitahara CM, et al
    Associations between artificial light at night and risk for thyroid cancer: A large US cohort study.
    Cancer. 2021 Feb 8. doi: 10.1002/cncr.33392.
    

    >> Share

    
    
13. YIP L, Gooding WE, Nikitski A, Wald AI, et al
    Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study.
    Cancer. 2021 Feb 4. doi: 10.1002/cncr.33421.
    

    >> Share

    
    January 2021
14. ALHUMAIDI H, Manochakian R, Cochuyt J, Chindris A, et al
    Initial treatment of patients with thyroid cancer: Outcomes and factors associated with care at academic versus nonacademic cancer centers.
    Cancer. 2021 Jan 15. doi: 10.1002/cncr.33408.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share